Combination of recombinant follicle stimulating hormone with human menopausal gonadotrophin or recombinant luteinizing hormone in a long gonadotrophin‐releasing hormone agonist protocol: a retrospective study

Raju, Gottumukkala Achyuta Rama; Teng, Shi Chao; Prathigudupu, Kavitha; Lakshmi, Balabomma Kavitha; Cheemakurthi, Ravikrishna

doi:10.1007/s12522-012-0120-2

Cited by 7 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some of the recent studies suggest that the indicators for adding LH to an ART cycle are mid follicular (day 6) hypo-response to long GnRH agonist, no follicles > 10 mm, E2 < 200 pg/ml, endometrial thickness < 6 mm and baseline serum LH < 1.2 IU/ml on day 6. [ 8 25 ]…”

Section: Role Of Lh In Physiology: the Physiological Hormonal Interplmentioning

confidence: 99%

See 1 more Smart Citation

Luteinizing hormone and follicle stimulating hormone synergy: A review of role in controlled ovarian hyper-stimulation

Raju¹,

Chavan²,

Deenadayal³

et al. 2013

J Hum Reprod Sci

109

View full text Add to dashboard Cite

Luteinizing hormone (LH) in synergy with follicle stimulating hormone (FSH) stimulates normal follicular growth and ovulation. FSH is frequently used in assisted reproductive technology (ART). Recent studies have facilitated better understanding on the complementary role of the LH to FSH in regulation of the follicle; however, role of LH in stimulation of follicle, optimal dosage of LH in stimulation and its importance in advanced aged patients has been a topic of discussion among medical fraternity. Though the administration of exogenous LH with FSH is obligatory for controlled ovarian stimulation in patients with hypogonadotropic hypogonadism, there is still a paucity of information of its usage in other patient population. In this review we looked in to the multiple roles that LH plays complementary to FSH to better understand the LH requirement in patients undergoing ART.

show abstract

Section: Role Of Lh In Physiology: the Physiological Hormonal Interplmentioning

confidence: 99%

“…[ 54 ] To achieve an optimal benefit Ramu et al suggested a dose of 75 IU/day of r-hLH for supplementation with r-HFSH. [ 25 ]…”

Section: Role Of Lh In Physiology: the Physiological Hormonal Interplmentioning

confidence: 99%

Luteinizing hormone and follicle stimulating hormone synergy: A review of role in controlled ovarian hyper-stimulation

Raju¹,

Chavan²,

Deenadayal³

et al. 2013

J Hum Reprod Sci

109

View full text Add to dashboard Cite

show abstract

“…When compared with increasing rHFSH dose, adding rLH on days 8 was associated with a better cumulative implantation rate (14.2 vs 10.5) and cumulative pregnancy rate (37.2 vs 29.3). 20,34,35 There are recommendations for the use of LH supple mentation in the ongoing cycle for patients with a his tory of prior poor response and patients who exhibit a sub optimal response during long agonist ovarian stimulation protocols. There is a possibility to opti mize the ovarian response in both these patient groups through the addition of rLH.…”

Section: Patients At Risk Of Hyporesponse During Ovarian Stimulationmentioning

confidence: 99%

Luteinizing Hormone in Controlled Ovarian Stimulation

Arveen¹

2014

International Journal of Infertility &Amp; Fetal Medicine

View full text Add to dashboard Cite

The role of follicle stimulating hormone (FSH) in assisted reproductive technology is well understood, though there is still no published consensus on the need for exogenous luteinizing hormone (LH) in controlled ovarian stimulation. There is a dilemma regarding the usefulness of LH supplementation in controlled ovarian stimulation despite growing understanding of the LH and FSH interrelation and their effects on fertilization and implantation. This review revisits the physiological role of LH, LH receptors and the concept of LH therapeutic window. With the availability of LH activity from different sources, there is a need to understand the differences between recombinant human LH (r-HLH), human menopausal gonadotropin and human chorionic gonadotropin (hCG). It has been observed that adjuvant r-HLH provides precise control over the dose of LH bioactivity administered to target the therapeutic window. This review discusses about the various patient subgroups that may benefit from LH supplementation. The use of r-HLH is recommended in women with poor response in a previous cycle or suboptimal follicular growth in an ongoing ovarian stimulation cycle by day 6 to 8 of stimulation. Exogenous LH administration should also be considered in women at risk of suboptimal response, specifically age > 35 years and women treated with GnRH analogues (agonists or antagonists) during ovarian stimulation causing over suppression of endogenous LH and FSH pituitary secretion. Further research is needed to identify LH polymorphisms, adequate dosing, cost efficacy, need for rLH and hCG supplementation in different patient profiles for maximum benefit during controlled ovarian stimulating (COS). How to cite this article Vohra A, Rao KA. Luteinizing Hormone in Controlled Ovarian Stimulation. Int J Infertil Fetal Med 2014; 5(3):75-86.

show abstract

“…LH is also critical for the differentiation of mature follicle to the corpus luteum, and maintain normal luteal function to ensure proper gonadal functioning ( 13 ). In our earlier study, in 2012 we reported better pregnancy rates when we replaced the use of r-hFSH plus hMG with r-hFSH plus r-hLH combination ( 14 ). Interestingly, we observed variable responses among the women receiving r-hLH supplementation.…”

Section: Introductionmentioning

confidence: 99%

Effect of LHCGR Gene Polymorphism (rs2293275) on LH Supplementation Protocol Outcomes in Second IVF Cycles: A Retrospective Study

Cheemakurthi²,

Madan³

et al. 2021

Front. Endocrinol.

View full text Add to dashboard Cite

Infertility is a major concern for couples wanting to have progeny. Despite recent advances in the field of IVF, success rates still need improvement. Understanding the patient’s variability and addressing it with personalized interventions may improve the success rate of fertilization and live births. This study examined the impact of a personalized pharmacogenomic approach on LH supplementation on the pregnancy and live birth rate outcomes in comparison with the traditional approaches. 193 patients undergoing a second IVF cycle in Krishna IVF Clinic received LH supplementation either as per the conventional methods or based on N312S (rs2293275) LHCGR gene polymorphism. Results showed a significant increase in pregnancy rate (P-value: 0.049) and a trend showing improvement in live birth rates (P-value: 0.082) when r-hLH supplementation protocol was decided as per the genotypes A/A, A/G, and G/G of the N312S variant in the respective patients. This stimulation regimen helped in providing optimum levels of r-hLH supplementation to patients with impaired hormone-receptor interacting activity, to achieve higher success in pregnancy and live birth rates.

show abstract

Combination of recombinant follicle stimulating hormone with human menopausal gonadotrophin or recombinant luteinizing hormone in a long gonadotrophin‐releasing hormone agonist protocol: a retrospective study

Cited by 7 publications

References 20 publications

Luteinizing hormone and follicle stimulating hormone synergy: A review of role in controlled ovarian hyper-stimulation

Luteinizing hormone and follicle stimulating hormone synergy: A review of role in controlled ovarian hyper-stimulation

Luteinizing Hormone in Controlled Ovarian Stimulation

Effect of LHCGR Gene Polymorphism (rs2293275) on LH Supplementation Protocol Outcomes in Second IVF Cycles: A Retrospective Study

Contact Info

Product

Resources

About